China
Africa
Explore chapters and articles related to this topic
HLA-DR and -DQ Serotyping
Published in M. Kam, Jeffrey L. Bidwell, Handbook of HLA TYPING TECHNIQUES, 2020
HLA-DR52, HLA-DR53, and HLA-DR51. The DR52 and DR53 specificities have absolute associations with the main DR types, therefore, confirmation of the main DR types can be provided by considering the reactions of the anti-DR52 and -DR53 reagents (see Table 5).
HLA-DRB1*04:05 and HLA-DQB1*04:01: Alleles Potentially Associated with Vogt-Koyanagi-Harada in Northern Thai Patients
Published in Ocular Immunology and Inflammation, 2021
Nampeung Anukul, Kessara Pathanapitoon, Nipapan Leetrakool, Tiphakorn Guntiya, Ratsameetip Wita, Poonsub Palacajornsuk, Phennapha Klangsinsirikul
Vogt-Koyanagi-Harada (VKH) syndrome is a multi-system, autoimmune disorder commonly presenting with granulomatous panuveitis, retinal detachment, and central nervous system abnormalities, which involve human leukocyte antigen (HLA). In Thailand, the frequency of VKH disease in non-HIV-positive patients is approximately 16%,1 but to date, there has been no report on HLA alleles linked to VKH in Thai patients. However, according to previous reports, VKH is strongly associated with HLA-DR4, HLA-DR53, and HLA-DQ4 in Japanese patients.2,3 Moreover, alleles HLA-DR4, HLA-DR53, and HLA-DQ7 are identified in Chinese patients.4 Likewise, expression of the DRB1*04:05 allele was detected in 75% of Vietnamese VKH patients.5 Given the over whelming number of previous reports that suggest the HLA-class II gene family could be the primary genetic factor linked to VKH susceptibility,2–15 this study focused on genotyping HLA class II locus alleles within HLA-DRB and DQB in our three subject groups: Thai patients with VKH, other uveitis entities, and healthy blood donors. Our findings will open new insights in HLA class II-associated VKH in Northern Thailand and may help to unravel the pathogenesis of VKH with unknown etiology.
Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro
Published in OncoImmunology, 2018
Miki Tsuruta, Shohei Ueda, Poh Yin Yew, Isao Fukuda, Sachiko Yoshimura, Hiroyuki Kishi, Hiroshi Hamana, Masatoshi Hirayama, Junji Yatsuda, Atsushi Irie, Satoru Senju, Eiji Yuba, Tomomi Kamba, Masatoshi Eto, Hideki Nakayama, Yasuharu Nishimura
As shown in Fig. 2A, after at least three rounds of stimulations, the Th cells established from an HLA-DR4- and HLA-DR53-positive HD (HD1) produced a significant amount of IFN-γ in response to DEPDC1-LP1-pulsed PBMCs in an HLA-DR-dependent manner as revealed by the enzyme-linked immunospot (ELISPOT) assays. The Th cells specifically recognized mouse fibroblast L cells expressing HLA-DR53 (DRB4#01:03; L-DR53) pulsed with DEPDC1-LP1 but did not recognize unpulsed L-DR53 cells, DEPDC1-LP1-pulsed L cells expressing HLA-DR4 (DRB1#04:05; L-DR4), or HLA-DR9 (DRB1#09:01; L-DR9). These results indicated that DEPDC1-LP1 was presented by HLA-DR53 and induced DEPDC1-LP1-specific Th-cell responses in an HLA-DR53-restricted manner. To investigate whether DEPDC1-LP1 could induce Th-cell responses restricted by other HLA class II molecules, CD4+ T cells from another HD (HD4) were tested. We confirmed that DEPDC1-LP1 induced HLA-DR4-restricted Th-cell responses (Fig. 2B). Thus, DEPDC1-LP1 bound to HLA-DR4 in addition to HLA-DR53 and induced peptide-specific Th-cell responses.
Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis
Published in Critical Reviews in Clinical Laboratory Sciences, 2021
Elena Savvateeva, Olga Smoldovskaya, Guzel Feyzkhanova, Alla Rubina
The serum level of the 14-3-3η protein was revealed as a new promising diagnostic marker for RA [42]. Tan et al. measured the levels of 14-3-3η protein, D-dimer, autoantibodies against CCP, Sa, and the genetic factors, HLA-DR4 and HLA-DR53, in 128 RA patients, 174 non-RA patients and 80 healthy donors [43]. The presence of each biomarker was associated with RA risk, with the odds ratios between RA and the control groups being 5.444 (HLA-DR4), 3.515 (HLA-DR53), 13.13 (14-3-3η protein), 9.8 (D-dimer), 153 (anti-CCP), and 17.561 (anti-Sa) with p < 0.01. It was also shown that the combination of RA biomarkers would aid in early diagnosis of RA.